^
Association details:
| Biomarker: | MLL rearrangement |
|---|---|
| Cancer: | Leukemia |
| Drug: | VTP-50469 (Menin-MLL inhibitor) + pinometostat (EPZ-5676) (DOT1L inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Variable Response of MLL-Rearranged Leukemia Cell Lines to Combinations of Menin, CDK9 and DOT1L Inhibitors
Published date:
11/02/2023
Excerpt:
The combination of VTP50469 (menin inhibitor) and EPZ5676 (DOT1L inhibitor) was superior in decreasing cell viability in MLL-r leukemia cell lines sensitive to VTP50469 (MV4;11, MOLM13 and RS4;11)...Based on our preclinical in vitro findings, the co-inhibition of menin-DOT1L or menin-CDK9 is a promising approach for the treatment of MLL-r leukemia.
DOI:
https://doi.org/10.1182/blood-2023-177700
